Angiodynamics
ANGO----
Q4 FY2026 EarningsQ4 FY26 results beat consensus on the top line with revenue of $86.6M vs. $80.2M expected, driven by 16.7% growth in the Med Tech segment. GAAP gross margin reached 54.0%, exceeding the 52.15% estimate, aided by a favorable shift toward high-margin platforms like NanoKnife (+64.5%). While Adjusted EPS of -$0.07 beat the -$0.09 consensus, GAAP loss per share of -$0.27 missed the -$0.18 estimate due to higher restructuring and CEO transition costs. FY27 revenue guidance of $336M-$341M aligns with market expectations, supported by a debt-free balance sheet.
Financial report interval: 2026.03.03 - 2026.05.31
Overview: Angiodynamics(ANGO) the Revenue is 86.61 M (+8.05%), Beat estimate;the EBIT is -2.794 M (-167.4%), Beat estimate;the EPS is -0.27 (-80%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.09B8.05%
0.08B0.11%
+0.01B7.94%
EBITExceed expectations
-0.00B167.37%
-0.01B684.69%
+0.01B517.32%
EPSMiss expectations
-0.2780.00%
-0.183322.22%
-0.086757.78%
Upcoming earnings report - Q1 FY2027
Available dateOct 8, 2026
Estimate Revenue$80.5 M
Estimate EBIT-$7 M
Estimate EPS-$0.1633
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf